Moderna-Merck vaccine plus Keytruda cuts recurrence and spread in first positive Phase 3 trial for the approach.
For patients who survive surgery for high-risk melanoma, the fear of the cancer returning has long hung over every scan. On Wednesday, that fear took a measurable hit.
Merck and Moderna announced that their personalized mRNA vaccine, intismeran autogene (also known as mRNA-4157 or V940), combined with Merck’s Keytruda, met its main goals in a large late-stage trial. The combination reduced the risk of cancer coming back and stopped it from spreading to distant sites better than Keytruda alone.
A First for mRNA Cancer Therapy
The Phase 3 INTerpath-001 trial enrolled 1,137 patients with stage IIB to IV melanoma whose tumors had been completely removed by surgery. Patients received either the custom vaccine plus Keytruda or Keytruda alone for about a year.
At a planned interim look, the dual treatment delivered statistically significant and clinically meaningful gains in recurrence-free survival and distant metastasis-free survival. No new safety problems appeared. The study continues to track overall survival.
This marks the first positive Phase 3 result for any individualized neoantigen therapy and the first for an mRNA-based cancer treatment. It is also the first time a regimen has clearly beaten Keytruda alone in the adjuvant melanoma setting.
How the Vaccine Works
Doctors sequence each patient’s tumor to identify unique mutations. Moderna then builds a one-of-a-kind mRNA shot that teaches the immune system to hunt up to 34 of those specific cancer markers. Given with Keytruda, which removes the brakes on T cells, the vaccine aims to create a lasting attack force against leftover cancer cells.
Earlier mid-stage data had already shown a 49 percent drop in the risk of recurrence or death and a 59 percent drop in distant metastasis risk after five years. The new larger trial now confirms the approach works on a bigger, more diverse group of patients.
In collaboration with @moderna_tx, we’re excited to share the first positive Phase 3 topline results for our investigational individualized neoantigen therapy (INT) in combination with our company’s immunotherapy in the adjuvant setting for certain patients with completely… pic.twitter.com/OojdKT5hX1
— Merck (@Merck) August 19, 2026
Why This Matters
Melanoma remains one of the deadliest skin cancers. Even after successful surgery, many high-risk patients see the disease return, often as metastases. Standard adjuvant Keytruda has already improved outcomes, yet the new combination appears to push the benefit further.
The companies plan to present full data at an upcoming medical meeting and discuss the results with regulators. If approved, the therapy could become a new option for thousands of patients each year. Trials of the same vaccine are already underway in lung, bladder, and kidney cancers.
Shares of Moderna jumped sharply on the news, reflecting investor hopes that mRNA technology can deliver lasting value beyond infectious disease vaccines.
The results remain interim. Full details and longer follow-up will determine the exact size of the benefit and the path to approval. Still, for a field that has waited decades for a true personalized cancer vaccine to succeed in a definitive trial, Wednesday’s announcement stands as a clear milestone.
Moderna and @Merck today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene, a novel investigational mRNA-based individualized neoantigen therapy jointly developed by Merck and Moderna, in combination… pic.twitter.com/v4DjH0r823
— Moderna (@moderna_tx) August 19, 2026
AI Disclosure: This article was created with the assistance of artificial intelligence tools and was reviewed and edited by the Glowls News editorial team before publication.